SCHEDULE: Citius Pharmaceuticals Retains Dominant Stake in Citius Oncology Following Public Offering

Citius Pharmaceuticals, Inc. maintains an 84.3% beneficial ownership in Citius Oncology, Inc. after Citius Oncology's recent public offering of common shares.

Summary

• Citius Pharmaceuticals, Inc. (the "Reporting Person") is the beneficial owner of 66,049,615 shares of Citius Oncology, Inc.'s common stock.
• This ownership represents approximately 84.3% of Citius Oncology, Inc.'s outstanding common stock.
• As of July 17, 2025, Citius Oncology, Inc. had 78,370,402 shares of common stock outstanding.
• On July 17, 2025, Citius Oncology, Inc. sold and issued 6,818,182 shares of its common stock in a public offering.
• The Reporting Person has sole voting and dispositive power over all 66,049,615 beneficially owned shares.

Sentiment

Score: 7

Explanation: The filing indicates a strong, controlling ownership stake by Citius Pharmaceuticals in Citius Oncology, which can be viewed positively for strategic stability. The successful public offering also suggests capital infusion for Citius Oncology. The filing is purely factual and does not contain negative disclosures.

Positives

• Citius Pharmaceuticals, Inc. maintains a significant controlling interest of 84.3% in Citius Oncology, Inc., indicating strong strategic alignment and control.
• Citius Oncology, Inc. successfully completed a public offering, issuing 6,818,182 new shares of common stock.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the factual disclosure of ownership and the recent public offering.

Management Comments

• The filing was signed by Leonard Mazur, Chief Executive Officer of Citius Pharmaceuticals, Inc.

Industry Context

This filing is a disclosure of a significant ownership stake by a parent company in its subsidiary following a public offering. It reflects a specific corporate structure and capital event rather than broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders of Citius Oncology, Inc. will see Citius Pharmaceuticals, Inc. as a dominant controlling shareholder, potentially influencing corporate decisions and strategic direction.
• New investors participating in the public offering have acquired shares in Citius Oncology, Inc.

Key Dates

Keywords

Citius Oncology, Citius Pharmaceuticals, Schedule 13D, Beneficial Ownership, Public Offering, Common Stock, Equity Stake, Controlling Interest